Featured

Status

All Statuses
  • Completed7

Health Topics

Any Category
Diseases
Male Urogenital Diseases
Urogenital Neoplasms
Clear Filters

Search Clinical Trials

7 Results
Completed
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
Patients with primary or recurrent low/intermediate-risk papillary urothelial carcinoma of the bladder will undergo resection of all but one marker lesion, measuring at least 6mm but no greater than 10mm, …
Baylor Role: Lead Sponsor
Completed
Health-Related Quality of Life in Patients With Bladder Cancer
OBJECTIVES: - To identify aspects of survivorship experience that differ by clinical risk (low risk vs high risk) in patients with non-invasive bladder cancer. - To collect and examine data …
Completed
Quality of Life and Symptom Management in Patients With Bladder Cancer
OBJECTIVES: Primary - To identify aspects of health-related quality of life (HRQOL) and symptom management in patients with non-invasive, low- or high-risk bladder cancer. - To obtain feedback on data …
Completed
Bladder Cancer Patient-Reported Outcomes
The purpose of this study is to identify aspects of the bladder cancer (BlCa) survivorship experience that differ by clinical risk at diagnosis. The investigators will collect cross-sectional data from …
Baylor Role: Lead Sponsor
Completed
Screening for Bladder Cancer
Reduction of cancer mortality is a stated goal of the National Cancer Institute. Cancer of the bladder is the 4th most commonly diagnosed cancer and 7th leading cause of cancer …
Baylor Role: Lead Sponsor
Completed
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a …
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role: Lead Sponsor